1. Medtech Insight
  2. >>Leadership

Diversity, More Advocacy Among Lobo’s Top Priorities As New AdvaMed Board Chair

Stryker CEO Kevin Lobo says while repeal of the medical device tax is his top issue, there are four main priorities he wants to work on over the next two years as industry advocate group AdvaMed’s board chair. They include better public engagement, increased advocacy work with the new Congress, advancing new technology – especially start-ups – and increasing diversity in the medtech industry.

Stryker CEO Kevin Lobo
• Source: Source: Stryker/ AdvaMed

While repealing the medical device excise tax is still the No. 1 issue for AdvaMed, Stryker Corp. CEO Kevin Lobo, who has been named the new AdvaMed board chair, has outlined four top priorities as he leads the lobby group for the next two years. Among his priorities is directly communicating with consumers and congressional leaders about the benefits of medical devices, getting new technology to patients, and increasing diversity in the medtech workforce.

Lobo, who was born in Canada to Indian parents, wears many hats. He’s been a board member at AdvaMed since...

More from Leadership

More from Medtech Insight

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 
• By Amanda Maxwell

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.